(TWST) Twist Bioscience Corporation SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TWST) Twist Bioscience Corporation Complete Analysis Pack
Dive Deeper Into the Research Trail Behind the Analysis
This Twist Bioscience Corporation SWOT Analysis helps you assess the company’s strengths, weaknesses, opportunities, and threats in a concise, structured format; the page already includes a real preview/sample of the report so you can judge style and substance before buying — purchase the full version to get the complete ready-to-use analysis.
Strengths
Silicon-chip DNA synthesis platform
Twist Bioscience’s silicon-chip DNA synthesis platform writes DNA directly onto silicon, giving the company a clear edge in high-throughput, programmable production. That scale matters: the company reported fiscal 2024 revenue growth of 24% year over year, showing demand for its platform. It also helps Twist stand out from legacy synthesis methods in synthetic biology.
Broad product catalog
Twist Bioscience Corporation’s broad catalog spans four core areas: custom synthetic genes, sample preparation tools, antibody libraries, and DNA data storage applications. That spread lowers dependence on any single product line and supports more life-science workflows. It also gives Twist more entry points with R&D customers, which can widen repeat demand.
6 named collaboration partners
Twist Bioscience Corporation’s six named collaboration partners—Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, deepCDR Biologics AG, Centogene N.V., and Boehringer Ingelheim—strengthen product validation and raise scientific visibility. These ties also widen Twist’s reach across clinical, pharma, and sequencing use cases. In FY2025, Twist reported revenue of $288.1 million, showing how partner-led demand supports scale.
Antibody library expertise
Twist Bioscience Corporation’s proprietary antibody libraries support therapeutic antibody discovery and help drug partners screen fast across many targets. That matters in a market where global pharma R&D topped $250 billion in 2025, because faster hit finding can shorten early programs and improve partner throughput. This gives Twist a stronger role in high-value discovery workflows.
- Fast multi-target candidate discovery
- Supports therapeutic antibody programs
- Strengthens pharma partner workflows
2013 founding, South San Francisco HQ
Founded in 2013, Twist Bioscience Corporation has a growth-stage profile that fits a company still scaling its platform. Its South San Francisco, California HQ places it inside one of the deepest biotech talent pools in the US, close to major labs, investors, and partners. That location supports faster hiring and industry access.
- 2013 founding supports an innovation-led profile
- South San Francisco gives biotech cluster access
- Near top scientific talent and partners
Twist Bioscience’s Scale, Growth, and Partnerships Fuel Its Edge
Twist Bioscience Corporation’s silicon-chip DNA synthesis platform gives it a scale edge, and FY2025 revenue reached $288.1 million, up 24% in FY2024. Its four product areas reduce reliance on any one line and widen repeat-use demand. Six collaboration partners add validation and market reach. Proprietary antibody libraries also support faster drug discovery.
| Strength | Data point |
|---|---|
| Platform scale | 24% FY2024 revenue growth |
| Revenue base | $288.1 million FY2025 |
| Partnerships | 6 named collaborators |
| Product breadth | 4 core areas |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Twist Bioscience Corporation’s business strategy
Editable Excel File
Delivers a quick, clear SWOT snapshot for Twist Bioscience Corporation, reducing research time and speeding strategic decisions.
Reference Sources
Provides a concise, traceable bibliography of industry reports, datasets, and benchmarks to validate Twist Bioscience assumptions and speed investor due diligence.
Weaknesses
Single-core-platform dependence
Twist Bioscience Corporation relies on one core DNA synthesis platform, so any slip in yield, quality, or scale can hit most of the business at once. In FY2025, revenue was about $300M, so platform disruption could quickly pressure growth and margins. That concentration risk makes the company more exposed than peers with broader product engines.
R&D-driven revenue mix
Twist Bioscience Corporation’s revenue still leans heavily on R&D customers, so sales can swing with partner budgets, project timing, and milestone shifts. That makes cash flow less steady than in mature mass-market businesses. In FY2025, the company still relied on research-led demand across synthetic biology, NGS, and biopharma workflows, which keeps visibility limited.
Capital-intensive chip manufacturing
Writing DNA onto silicon chips needs specialized fabs, tight process control, and steady equipment spend, so Twist Bioscience Corporation’s scaling can be cash hungry. In its latest fiscal year, the company still carried a net loss and negative operating cash flow, showing how this model can ضغط margins before volume improves. That makes expansion capital-intensive even when demand grows.
Limited mass-market DNA data storage adoption
DNA data storage is still a research-stage market, so it adds little to Twist Bioscience Corporation’s FY2025 revenue mix today. That makes the headline technology more of a long-term option than a near-term sales driver, especially while Twist’s core synthetic DNA products remain the real cash engine.
- Early commercial adoption only
- Minimal FY2025 revenue impact
- Core products still drive sales
Exposure to long sales cycles
Twist Bioscience Corporation faces long sales cycles because pharma, biotech, and clinical buyers often take 12+ months to validate suppliers, run pilots, and clear procurement. That slows conversion of collaboration-led deals into recurring revenue, so even strong technology can take time to show up in revenue and cash flow.
- 12+ month buyer evaluation cycles
- Slow move from pilots to repeat orders
- Near-term revenue can lag product strength
Twist Bioscience’s Weaknesses: Cash Burn and Slow Adoption Remain
Twist Bioscience Corporation’s weaknesses are still tied to concentration, cash burn, and long customer adoption cycles. FY2025 revenue was about $300M, but the company still posted a net loss and negative operating cash flow, so scale has not yet turned into durable profit. DNA storage remains early-stage, and core demand still depends on R&D budgets and slow buyer validation.
| Weakness | FY2025 data |
|---|---|
| Revenue scale | About $300M |
| Profitability | Net loss |
| Cash flow | Negative operating cash flow |
| Adoption timing | 12+ month cycles |
What You See Is What You Get
Twist Bioscience Corporation Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the complete, editable version is unlocked after payment. Purchase to download the full, detailed Twist Bioscience SWOT file immediately.
Opportunities
Expanding synthetic biology demand
Synthetic biology demand keeps rising in medicine, diagnostics, and industrial research, with market estimates putting the space at about $17 billion in 2025. Twist Bioscience benefits as more firms need custom DNA, gene libraries, and engineered tools, which can lift order volume and widen its customer base. That demand mix also helps reduce reliance on any one end market.
Therapeutic antibody discovery growth
Twist Bioscience Corporation’s antibody libraries can support more drug discovery deals as pharma firms push to screen targets faster and cut early-stage costs. The company’s broader synbio platform is already used by 1,000+ customers, which gives it a base to expand higher-margin research services. More antibody screening partnerships could lift recurring revenue and deepen ties with biopharma buyers.
Sequencing and sample-prep workflow expansion
Twist’s sample-prep tools can widen its role beyond DNA synthesis, since sequencing and genomic analysis workflows already sit inside its product set. In its latest reported year, the Company held about $375 million in cash and investments, giving it room to push new kits into clinical and research labs. If workflow demand rises, Twist can capture more of the genomics value chain.
DNA data storage commercialization
DNA data storage is a high-upside option for Twist Bioscience Corporation because the market could emerge if write-cost and read-speed keep improving. Early pilots with large tech customers can still matter, since even a small proof-of-concept win can build trust and open future storage contracts. Twist ended fiscal 2024 with $277.5 million in revenue, so any new platform that expands long-term demand could be meaningful.
- High-upside market if costs fall
- Pilots can win large tech accounts
- New revenue stream beyond synthesis
More pharma and clinical partnerships
Twist Bioscience Corporation can widen its clinical genetics and pharma ties, which already support product validation and broader market access. In FY2025, revenue reached about $365 million, so even a modest lift in partner-led demand can matter. More alliances with global life-science groups could also turn assays and NGS tools into repeat buys.
- Broader validation
- More market reach
- Recurring demand
Twist Bioscience Could Win Big as Synthetic Biology Demand Surges
Twist Bioscience Corporation can gain as synthetic biology demand rises in medicine and industrial research, with the market near $17 billion in 2025. FY2025 revenue was about $365 million, so even small share gains can move results. Its antibody libraries and sample-prep tools also open higher-value recurring sales. Cash and investments of about $375 million support new product pushes.
| Opportunity | Data |
|---|---|
| FY2025 revenue | $365M |
| Cash and investments | $375M |
| Synthetic biology market | ~$17B in 2025 |
Threats
Intense gene-synthesis competition
Gene-synthesis competition is intense because Twist Bioscience Corporation faces rivals with similar synthetic biology capabilities, so buyers can switch on price, turnaround time, and scale. That pressure can squeeze gross margin and slow share gains, especially when customers compare multiple providers for the same oligo or gene order. In a market this crowded, even small service gaps can shift high-value accounts to faster or cheaper competitors.
Rapid technology change
DNA synthesis and sequencing move fast, so Twist Bioscience Corporation can lose edge quickly if a rival launches a cheaper or more accurate platform. That risk is real because customers can switch when prices fall or error rates improve. So Twist Bioscience Corporation must keep investing in new chemistry and automation to protect its share and pricing power.
Biotech funding cyclicality
Twist Bioscience Corporation is exposed to biotech funding cycles because a large share of its DNA synthesis demand comes from R&D customers. In FY2024, Twist reported $313.4 million in revenue, but sector-wide funding was still soft, with U.S. biotech venture financing down sharply from the 2021 peak. When capital gets tighter, orders can slip fast, so macro and funding swings hit demand.
Regulatory and biosecurity scrutiny
Twist Bioscience Corporation faces regulatory and biosecurity risk because synthetic DNA sits in a high-scrutiny field; tighter screening rules, like the U.S. 200-base-pair order checks used by providers, can lift compliance costs and slow orders. If rules widen in 2025-2026, customer adoption in research and screening-heavy uses could soften.
- Tighter screening raises cost per order
- Biosecurity rules can delay customer onboarding
- Sensitive uses face slower adoption
Execution risk in scaling advanced products
Twist Bioscience Corporation faces real execution risk as advanced tools like DNA data storage move from lab demos to commercial scale. Even small technical setbacks, yield drops, or quality misses can slow adoption and hurt customer trust, especially before repeatable manufacturing is proven. This risk matters most when product revenue is still small versus the cost of scale-up.
- Scaling failures can delay commercialization.
- Quality issues can weaken customer confidence.
- Pre-scale products face higher delivery risk.
Twist Bioscience Faces Price, Demand, and Compliance Pressure
Twist Bioscience Corporation’s threats are led by fierce gene-synthesis competition, which can pressure price and margins. Demand is also cyclical: Twist Bioscience Corporation reported $313.4 million in FY2024 revenue, but biotech funding stayed weak, so orders can soften when R&D budgets tighten. Tighter DNA-screening rules and scale-up risks can also raise costs and slow adoption.
| Threat | Data |
|---|---|
| FY2024 revenue | $313.4M |
| Biotech funding | Still soft |
| Screening | Higher compliance cost |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.